Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
April 22 2024 - 5:31PM
Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating
genetic medicines for people living with rare and prevalent
diseases, today announced that six abstracts highlighting
preclinical data from its cell-targeted lipid nanoparticle (ctLNP)
and immune-quiet DNA (iqDNA) platforms have been accepted for
presentation, including one oral presentation, at the American
Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking
place May 7-11, 2024 in Baltimore, MD.
“We are delighted to have a robust presence at this year’s ASGCT
meeting and showcase some of the innovative technical work
underpinning the breakthroughs we have achieved for our
cell-targeted lipid nanoparticle (ctLNP) and immune-quiet DNA
(iqDNA) platforms,” said Matt Stanton, Ph.D., chief scientific
officer. “We’ve made rapid progress across our platforms and look
forward to presenting further updates at the meeting.”
Oral Presentation
Title: Highly Specific, In Vivo Delivery to
T-Cells with Cell-Targeted Lipid
NanoparticlesSession: Targeting Specific Cell
Types with Nonviral DeliverySession Location: Room
314-317Session Date/Time: Saturday, May 11, 8:00
a.m. – 9:45 a.m. ETPresentation Time: 8:35 a.m. –
9:10 a.m. ET
Poster Presentations
Title: iqDNA Is an Engineered DNA Cargo That
Avoids Innate Immune Activation While Retaining Durable Transgene
ExpressionSession: Challenges to Immunological
Responses to Therapeutic InterventionsSession
Date/Time: Thursday, May 9, 2024, 12:00 p.m. ET – 7:00
p.m. ETAbstract Number: 1294
Title: Rapid Enzymatic Synthesis and Scaling of
DNA Gene Therapy MoleculesSession: Nonviral
Therapeutic Gene Delivery and Synthetic/Molecular
ConjugatesSession Date/Time: Thursday, May 9,
12:00 p.m. – 7:00 p.m. ETAbstract Number: 1232
Title: Optimization of Ionizable Lipid
Structure to Modulate ApoE Binding and Enable Stealth Lipid
NanoparticlesSession: Other Nonviral
DeliverySession Date/Time: Thursday, May 9, 12:00
p.m. ET – 7:00 p.m. ETAbstract Number: 1240
Title: Development of Cell-Targeted Lipid
Nanoparticles Using Antibody Derived Ligands for Targeted Delivery
to Hepatocytes and Immune CellsSession: Nonviral
Therapeutic Gene Delivery and Synthetic/Molecular
ConjugatesSession: Other Nonviral
DeliverySession Date/Time: Thursday, May 9, 12:00
p.m. ET – 7:00 p.m. ETAbstract Number: 1241
Title: In Vivo High-Throughput Pooled Screening
of Transcriptional Regulatory Elements for Gene Therapy
Session: Nonviral Therapeutic Gene Delivery and
Synthetic/Molecular ConjugatesSession Date/Time:
Thursday, May 9, 12:00 p.m. ET – 7:00 p.m. ETAbstract
Number: 1233
The ASGCT abstracts are available to the public here. A copy of
the presentation materials will be added to the “Our Scientific
Presentations” section of the company’s website here on the day of
each presentation.
About Generation Bio
Generation Bio is innovating non-viral genetic medicines to
provide durable and redosable treatments for hundreds of millions
of patients living with rare and prevalent diseases. The company is
developing two distinct and complementary platforms: a potent,
highly selective cell-targeted lipid nanoparticle (ctLNP) delivery
system and a novel immune-quiet DNA (iqDNA) cargo produced by a
scalable capsid-free manufacturing process that uses proprietary
cell-free rapid enzymatic synthesis (RES). With these platforms,
Generation Bio aims to develop the next wave of non-viral genetic
medicines to support its mission to extend the reach of genetic
medicine to more people living with more diseases, around the
world.
For more information, please visit www.generationbio.com.
Investors and Media ContactMaren
KillackeyGeneration
Biomkillackey@generationbio.com 857-371-4638
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From Jul 2023 to Jul 2024